Alaska Air, BP, Nomura, Pozen, Sabesp: U.S. Equity Preview

May 2 (Bloomberg) -- Shares of the following companies may have unusual moves in U.S. trading tomorrow. Stock symbols are in parentheses, and prices are as of 5:20 p.m. in New York unless otherwise noted.

Alaska Air Group Inc. (ALK:US): The airline may rise as much as 40 percent as the traffic around Seattle and Hawaii improves, and industry consolidation leaves fewer competitors, Barron’s reported.

BP Plc (BPAQF:US): Europe’s largest oil and gas company and Transocean Ltd. (RIG:US) are among companies that may rebound after the shares were sold amid concern over the remediation costs of an oil spill in the Gulf of Mexico, Barron’s reported. Oil companies affected by the spill, which began April 20, including Anadarko Petroleum Corp. (APC:US) and Halliburton Co. (HAL:US), have lost a combined $40 billion in market value, the weekly newspaper said in its May 3 edition.

Cia. De Saneamento Basico do Estado de Sao Paulo (SBS:US): Brazil’s biggest water utility, also known as Sabesp, may rise as the nation’s economy rebounds and global demand for clean water expands, Barron’s reported.

General Growth Properties Inc. (GGP:US): The mall owner’s bankruptcy court hearing on its auction process was pushed back one day to give the company more time to evaluate competing investment plans. The hearing will be on May 5, General Growth said.

Integral Systems Inc. (ISYS:US): The maker of Epoch Client satellite systems and software said Bill Bambarger resigned as chief financial officer because of personal and health reasons.

Nomura Holdings Inc. (NMR:US): Japan’s biggest brokerage may rise as it adds staff and expands in global markets, including the U.S., Barron’s reported.

Popular Inc. (BPOP:US): Puerto Rico’s largest bank said it acquired assets and assumed all retail deposit liabilities of Westernbank Puerto Rico, which was closed by regulators.

Pozen Inc. (POZN:US) surged 28 percent to $13.91 in extended trading. The drugmaker and partner AstraZeneca Plc (AZN:LN) won U.S. clearance to sell an arthritis drug that combines a painkiller with an ulcer medication.